DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

Information source: Alfa Wassermann S.p.A.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: BACTERIAL VAGINOSIS

Intervention: RIFAXIMIN VAGINAL TABLET 25 MG (Drug); RIFAXIMIN VAGINAL TABLET 100 MG (Drug); PLACEBO VAGINAL TABLET (Drug); METROGEL VAGINAL (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Alfa Wassermann S.p.A.

Official(s) and/or principal investigator(s):
Raffaella Tacchi, MD, Study Director, Affiliation: Alfa Wassermann S.p.A.

Overall contact:
Gary Spivak, Phone: +1 978.495.4191, Email: gary.spivak@parexel.com

Summary

THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS

Clinical Details

Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: CLINICAL CURE OF BACTERIAL VAGINOSIS

Secondary outcome:

BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS

THERAPEUTIC CURE OF BACTERIAL VAGINOSIS

MAINTENANCE OF CLINICAL CURE OF BACTERIAL VAGINOSIS

MAINTENANCE OF BACTERIOLOGICAL CURE OF BACTERIAL VAGINOSIS

MAINTENANCE OF THERAPEUTIC CURE OF BACTERIAL VAGINOSIS

NUMBER, INTENSITY AND TYPE OF ADVERSE EVENTS

LOCAL OBJECTIVE TOLERABILITY

LOCAL SUBJECTIVE TOLERABILITY

Detailed description: THIS IS A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY PLANNING TO ENROL 626 SUBJECTS AFFECTED BY BACTERIAL VAGINOSIS. PRIMARY ENDPOINT: TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS SECONDARY ENDPOINT: TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS METROGEL VAGINAL IN SUBJECTS WITH BACTERIAL VAGINOSIS.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Clinical diagnosis of bacterial vaginosis with Amsel's criteria (4 out of 4 fulfilled

criteria):

- Off white (milky or gray), thin, homogeneous, adherent vaginal discharge

- pH >4. 5

- Positive "whiff test"

- Presence of clue cells ≥20%

- Bacteriological diagnosis of bacterial vaginosis with Gram stain Nugent score ≥ 4

(patients may be enrolled/randomized without this result)

- Post-menarchal, pre-menopausal female patient

- Non-pregnant (negative urine pregnancy test at Entry Visit/V1) nor breast-feeding

patient

- Patient aged between 18 50 years, inclusively

- Patient who is willing to be asked questions about personal medical health and sexual

history

- Patient capable of and willing to conform to the study protocol

- Patient who have been thoroughly informed of the aim of the study and the study

procedures and who provided signed and dated written informed consent form

- Patient who agrees to abstain from intercourse during the 5 day treatment period

- Patient who agrees also to abstain from intercourse 3 days before the scheduled

visits of follow-up

- Patient who agrees to abstain from the use of any other intravaginal product (i. e.,

douching, feminine deodorants sprays, tampons, spermicides, gels, foams, vaginal birth control ring and diaphragms) during the entire study period

- Patient who agrees to use an adequate method of birth control for the duration of the

study to avoid pregnancy. Acceptable methods include a history of bilateral tubal ligation, male partner with a vasectomy, a hormonal contraceptive [oral, patch, injectable or implantable (excluding intrauterine implantable devices [IUD], intrauterine system [IUS] and vaginal rings), or abstinence

- Patient who agrees to abstain from alcohol ingestion during the 5-day treatment

period and for 1 day afterward Exclusion Criteria:

- Virginity

- Patient with other infectious causes of vulvovaginitis (e. g., candidiasis,

Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex lesions, or Human Papilloma Virus lesions); patients may be enrolled/randomized without these results)

- Other vulvovaginal or cervical conditions, abnormalities or disorders confounding the

interpretation of clinical response (including total hysterectomy)

- Symptoms suggestive of pelvic inflammatory disease

- Patient with intra uterine device (IUD), intrauterine system (IUS), or vaginal ring

as contraceptive method

- Patient with severe hepatic insufficiency (Child C)

- Patient with severe cardiac insufficiency (NYHA - New York Heart Association classes

3 - 4)

- Patient who will be being evaluated, including colposcopy and cervical biopsies, or

being treated during the study period, for abnormal Pap test or cervical carcinoma. To note that if the Pap test will be performed at baseline, the result will be known after the randomization visit: patients may be enrolled without this result

- Any condition or circumstance that would prevent completion of the study or interfere

with analysis of study results, including a history of drug or alcohol abuse, mental illness or non-compliance with treatments or visits, immunological (including HIV infection), hematological or neoplastic disease (including all cervical neoplastic diseases)

- Cervical cryotherapy, loop electrosurgical excision (LEEP), cervical laser, or any

other ablative or excisional cervical procedures within the last 3 months

- Vaginal laser within the last 3 months

- Patient with clinically relevant pathological laboratory values

- Known hypersensitivity to rifaximin

- Known hypersensitivity to excipients present in rifaximin, placebo or metronidazole

formulations

- Known hypersensitivity to metronidazole, either orally or topically administered, or

any forms of parabens

- Concurrent anticoagulant therapy with coumadin or warfarin

- Menstruating or anticipated menstruation/withdrawal bleed at Entry Visit/V1 and

during the drug administration

- Patient who received antifungal or antimicrobial therapy (systemic or intravaginal)

within 14 days of randomization

- Patient who have participated in another clinical trial or have taken an

investigational drug within the last 4 weeks prior screening

- Patient who has taken disulfuram within the last 14 days

- Withdrawal of informed consent

- Patient previously randomized in this study

Locations and Contacts

Gary Spivak, Phone: +1 978.495.4191, Email: gary.spivak@parexel.com

College of Medicine Drexel University, Philadelphia, Pennsylvania 191012-1192, United States; Recruiting
Paul Nyirjesy, MD, Phone: 215-762-1503, Email: Paul.Nyirjesy@DrexelMed.edu
Cheryl Tocci, RN, BSN, Phone: 215-762-8582, Email: tocci@drexelmed.edu
Additional Information

Starting date: March 2015
Last updated: June 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017